【24h】

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.

机译:抗精神病性非典型性的α-肾上腺素受体调节假说。

获取原文
获取原文并翻译 | 示例
           

摘要

Although all currently used antipsychotic drugs act as dopamine (DA) D2 receptor antagonists, clozapine, the prototype for atypical antipsychotics, shows superior efficacy, especially regarding negative and cognitive symptoms, in spite of a significantly reduced central D2 receptor occupancy compared with typical (conventional) antipsychotic drugs. Clozapine, as well as several other atypicals, displays significant affinities also for several other neurotransmitter receptors, including other dopaminergic receptors, alpha-adrenergic receptors and different serotonergic and cholinergic receptors, which in several ways may contribute to the clinical effectiveness of the drugs. Preclinical and clinical results suggest a dysregulated mesocorticolimbic DA system in schizophrenia, with an impaired prefrontal DA projection, which may relate to negative and cognitive symptoms, concomitant with an overactive or overreactive striatal DA projection, with bearing on psychotic (positive) symptomatology. Available data suggest that blockage of alpha1-adrenoceptors by antipsychotics may contribute to suppress positive symptoms, especially in acute schizophrenia, whereas alpha2-adrenoceptor blockage, a prominent effect of clozapine and, to some extent, risperidone but not other antipsychotics, may rather be involved in relief of negative and cognitive symptoms. Whereas alpha1-adrenoceptor blockage may act by suppressing, at the presynaptic level, striatal hyperdopaminergia, alpha2-adrenoceptor blockage may act by augmenting and improving prefrontal dopaminergic functioning. Thus, the prominent alpha1- and alpha2-adrenoceptor blocking effects of clozapine may generally serve to stabilize dysregulated central dopaminergic systems in schizophrenia, allowing for improved efficacy in spite of a reduced central D2 receptor occupancy compared with typical antipsychotic drugs.
机译:尽管目前所有使用的抗精神病药物均充当多巴胺(DA)D2受体拮抗剂,但与典型的(传统)抗精神病药。氯氮平以及其他几种非典型药物对其他几种神经递质受体也表现出显着的亲和力,包括其他多巴胺能受体,α-肾上腺素能受体以及不同的血清素能和胆碱能受体,这在几种方面可能有助于药物的临床有效性。临床前和临床结果表明,精神分裂症的中皮层皮质DA系统失调,前额叶DA投影受损,可能与阴性和认知症状有关,伴有纹状体DA过度活跃或过度反应,并伴有精神病(阳性)症状。现有数据表明,抗精神病药对α1-肾上腺素受体的阻滞可能有助于抑制阳性症状,特别是在急性精神分裂症中;而氯氮平的显着作用α2-肾上腺素受体阻滞剂,在某种程度上是利培酮,而不是其他抗精神病药,可能参与减轻负面和认知症状。尽管α1-肾上腺素受体阻滞可能通过在突触前水平抑制纹状体多巴胺痛而发挥作用,而α2-肾上腺素受体阻滞可能通过增强和改善额叶前多巴胺能功能发挥作用。因此,氯氮平的显着α1-和α2-肾上腺素受体阻断作用通常可用于稳定精神分裂症中失调的中央多巴胺能系统,尽管与典型的抗精神病药物相比,中央D2受体的占用减少,但仍可提高疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号